P: Adults (≥18 years of age) with CKD and type 2 diabetes (T2D), estimated glomerular filtration rate (eGFR) of 30–90 mL/min/1.73 m2 and UACR of ≥100 to <5000 mg/g.
I: EMPA+FINE combo
C: Empagliflozin vs Finerenone
O: At day 180, the reduction in the UACR with combination therapy was 29% greater than that with finerenone alone (least-squares mean ratio of the difference in the change from baseline, 0.71; 95% confidence interval [CI], 0.61 to 0.82; P<0.001) and 32% greater than that with empagliflozin alone (least-squares mean ratio of the difference in the change from baseline, 0.68; 95% CI, 0.59 to 0.79; P<0.001).
Uthando Nethemba 